Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1998-05-08
2002-12-03
Nguyen, Dave T. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200, C435S320100
Reexamination Certificate
active
06489305
ABSTRACT:
BACKGROUND OF THE INVENTION
Gene therapy has been proposed as an approach to the treatment of ocular diseases by a number of investigators. Hermens et al. (
J. Neurosci. Methods
71:85-98 (1997)) disclosed the injection of an adenoviral vector containing a lacZ gene as a reporter gene into the central and peripheral nervous system of the rat. In that system areas with a laminar structure such as the eye demonstrated more widespread transgene expression. Ali et al. (
Hum. Mol. Genet.
5:591-5949 (1996)) disclosed the use of an adeno-associated virus (AAV) as a vector carrying lacZ to transduce all layers of the neuroretina as well as the retinal epithelium following subretinal injection. Mashhour (
Gene Ther.
1:122-126 (1994)) disclosed that injection of an adenovirus vector carrying lacZ into the vitreous body, the anterior chamber, or the peribulbar body of mice did not result in any detectable cytopathic effect and was associated with endocytosis of viral particles in corneal, photoreceptor, bipolar, ganglionic, and oculomotor muscle cells, depending on the administration route.
The use of gene therapy to treat heritable diseases of the eye in particular has been proposed by several researchers. For example, Li et al. (
Proc. Natl. Acad. Sci. U.S.A.
92:7700-7704 (1995)) disclosed the use of adenovirus-mediated transfer of human beta-glucuronidase cDNA expressed under the control of a non-tissue specific promoter injected intravitreally or subretinally to reverse the pathological changes of lysosomal storage disease in the eyes of mice with mucopolysaccharidosis VII.
Rescue of photoreceptors by gene therapy has been demonstrated in several experimental systems. Cayouette and Gravel (
Hum. Gene Ther.
8:423-430 (1997)) disclosed adenovirus-mediated gene transfer of ciliary neurotropic factor prevented photoreceptor degeneration in the retinal degeneration (rd) mouse, an animal model of retinitis. pigmentosa Bennett et al. (
Hum. Gene Ther.
7:1763-1769 (1996)) disclosed the rescue of photoreceptor cells in rd mice using a recombinant replication defective adenovirus containing murine cDNA for beta phosphodiesterase. Dunaeif et al. (
Hum. Gene Ther.
6:1225-1229 (1995)) disclosed retroviral gene transfer into retinal pigment epithelial cells followed by transplantation into rat retina in an experimental rat model to preserve photoreceptors.
The use of suicide genes delivered by recombinant viral vectors to kill ocular cells has focused mainly on the use of the herpes thymidine kinase gene. For example, Sakamoto, et al. (
Ophthalmology
102:1417-1424 (1995) described the inhibition of experimental proliferative vitreoretinopathy by retroviral vector-mediated transfer of the herpes simplex thymidine kinase gene. Murata et al. (
Ophthalmic Res.
29:242-251 (1997) described the use of retroviral vectors to transfer the herpes simplex virus thymidine kinase gene in a rabbit model of proliferative vitreoretinopathy.
The role of tumor suppressor genes such as p16, p21, p53, or RB in hyperproliferative diseases of the eye has been challenging to elucidate. Studies of cell cycle regulation in the ocular lens using transgenic mice have shown that inactivation of RB can cause postmitotic lens fiber cells to enter the cell cycle. However, when p53 is present, inactivation of RB in this cell type results in cell death rather than continued proliferation. Although p53 is known to upregulate expression of the cyclin-dependent kinase inhibitor p21, overexpression of p21 in transgenic lens is not sufficient to cause apoptosis in transgenic mouse lens (Fromm et al.
Dev. Genet.
20:276-287 (1997)). In vascular tissue, Chang et al. (
J. Clin. Invest.
96:2260-2268 (1995)) discloses that adenovirus mediated overexpression of p21 inhibits vascular smooth muscle cell (VSMC) proliferation in vitro by arresting VSMCs in the G1 phase of the cell cycle. In addition, Chang, et al. demonstrated that localized adenoviral delivery of p21 in conjunction with balloon angioplasty significantly reduced neointima hyperplasia in the rat carotid artery model of restenosis.
SUMMARY OF THE INVENTION
The present invention discloses methods and compositions for the treatment of ocular diseases. In particular, the present invention provides a method for the treatment of ocular hyperproliferative diseases by the administration of cyclin dependent kinase inhibitors. The present invention further provides pharmaceutical formulations for the intracellular delivery of cyclin dependent kinase inhibitors.
REFERENCES:
patent: 5302706 (1994-04-01), Smith et al.
patent: 5621082 (1997-04-01), Xiong et al.
patent: 5624819 (1997-04-01), Skolnick et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5827702 (1998-10-01), Cuthbertson
patent: 6027742 (2000-02-01), Lee et al.
patent: 6218372 (2001-04-01), Nabel et al.
patent: 6242201 (2001-06-01), Lane et al.
patent: 6274614 (2001-08-01), Richter et al.
patent: B-61444/94 (1994-09-01), None
patent: WO 9409135 (1994-04-01), None
patent: WO 9528483 (1995-10-01), None
patent: 96/14334 (1996-05-01), None
patent: WO 9619244 (1996-06-01), None
patent: WO 9635704 (1996-11-01), None
patent: WO 9703635 (1997-02-01), None
patent: WO 9711174 (1997-03-01), None
patent: WO 97/37542 (1997-10-01), None
US 5,691,198, 11/1997, Jin et al. (withdrawn)
A. Divan, et al., “p53 Expression Correlates with Apoptosis but not with p21, waf Expression in Retinoblastomas”;Journal of Pathology(1997), vol. 182, pp. 6A.
A.F. Wright, “Gene therapy for the eye”;Br.J. Ophthalmol(Aug. 1, 1997), 81: pp. 620-623.
C.A. Schubert, et al. “Retrovirus-mediated transfer of the suicide gene into retinal pigment epithelial cells in vitro”;Curr. Eye Res.(Jul. 1, 1997), 16: pp. 656-662.
L. da Cruz, et al., “Ocular gene therapy: The basic science and current state of research”;Aust N.Z. J. Ophthalmol.(May 1, 1997), 25: pp. 97-104.
H.J. Xu, “Strategies for Approaching Retinoblastoma Tumor Suppressor Gene Therapy”;Adv. Pharmacol.(Jan. 1, 1997), 40: pp. 369-397.
N.G. Della, “Molecular Biology in Ophthalmology.A Review of Principles and Recent Advances.” Arch. Opthhalmol.(Apr. 1, 1996), 114: 457-463.
R.B. Nussenblatt, et al., “Perspectives on Gene Therapy in the Treatment of Ocular Inflammation.”;Eye(1997), 11: pp. 217-221.
D. Stephan, et al., “Gene and other biological therapies for vascular diseases.”;Fundam Clin. Pharmacol.(Jan. 1997), 11: pp. 97-110.
J.A. Eastham, et al., “In vivo gene therapy with p53 or p21 Adenovirus for Prostate Cancer.”;Cancer Res.(Nov. 15, 1995), 55: pp. 5151-5155.
D.T. Denhardt, “Oncogene-Initiated Aberrant Signaling Engenders the Metastatic Phenotype: Synergistic Transcription Factor Interactions are Targets for Cancer Therapy.”;Crit. Rev. Oncog.(1996), 7(3-4): 261-291.
A.L. Gartel, et al., “p21—Negative Regulator of the Cell Cycle.”;Proc. Soc. Exp. Biol. Med.(Nov. 1996), 213: pp. 138-149.
S.D. Morgenbesser, et al., “p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens.”;Nature(Sep. 1, 1994), 371(6492): 72-74.
David A. Alcorta, “Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.”;Proc. Natl. Acad. Sci.(1996), 93: pp. 13742-13747.
Elisa A. Spillare, “Suppression of Growth in Vitro and Tumorigenicity in Vivo of Human Carcinoma Cell Lines by Transfected p16INK4”;Mol. Carcinog.(1996), 16: 53-60.
Corinne Cayrol, et al., “p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells”;Oncogene(1998), 16: 311-320.
Joseph A. Erhardt, et al., “p21WAF1induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells.”;Oncogene(1998) 16: 443-451.
René H. Medema, et al., “p21waf1can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases”;Oncogene(1998) 16: 431-441.
Ali et al.,Hum. Mol. Genet.(1996) 5: 591-594.
Arteaga et al.,Cancer Research(1996) 56(5): 1098-1103.
Bennett et al.,Hum. Gene Ther.(1996) 7: 1763-1769.
Cayouette and Gravel,Hum. Gen Ther.(1997) 8: 423-430.
Chang et al.,J. Clin. Inve
Canji Inc.
Nguyen Dave T.
Townsend and Townsend / and Crew LLP
LandOfFree
Methods and compositions for the treatment of ocular diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of ocular diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of ocular diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2960896